National and regional changes in Methicillin-resistant *Staphylococcus aureus* type in bloodstream infections impact mortality

**Short title:** Changing MRSA types in BSIs

Norihito Kaku[a,b*], Masaki Ishige[b], Go Yasutake[a,b], Daisuke Sasaki[b], Kenji Ota[a,b], Fujiko Mitsumoto-Kaseida[a,b], Kosuke Kosai[a,b], Hiroo Hasegawa[a,b], Koichi Izumikawa[c], Hiroshi Mukae[d], Katsunori Yanagihara[a,b]

[a]Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, Japan 852-8501

[b]Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki City, Nagasaki, Japan 852-8501

[c]Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, Japan 852-8501

[d]Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki City, Nagasaki, Japan 852-8501

**[*]Corresponding Author:**

Norihito Kaku

1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan 852-8501

Email: norihitk@gmail.com

Tel: +81-95-819-7574 Fax: +81-95-819-7422

**Summary**

**Objectives:**

A 2019 nationwide study in Japan revealed the predominant MRSA types in bloodstream infections (BSI) to be ST8-carrying SCC*mec* type IV (ST8-IV) and clonal complex 1-carrying SCC*mec* type IV (CC1-IV). However, the patient characteristics of the major MRSA types and how they change over time remain unknown.

**Methods:**

MRSA strains isolated from blood cultures at Nagasaki University during 2012–2019 were sequenced. The SCC*mec* types and patient characteristics identified from this and previous studies (conducted during 2003–2007 and 2008–2011) conducted at our hospital were compared. Additionally, patient and molecular characteristics among the major MRSA types were compared.

**Results:**

Between 2003–2007 and 2016–2019, SCC*mec* type II decreased from 79.2% to 15.5%, whereas type IV increased from 18.2% to 65.5%; severity and outcomes also changed, and SOFA score decreased from 5.8 ± 0.5 to 3.1 ± 0.5, whilst in-hospital mortality decreased from 39.8% to 15.5%. No changes in patient background such as age, sex, or underlying diseases were observed. The most common MRSA types detected between 2012 and 2019 were ST8-IV (37.6%), ST8-I (22.4%), ST5-II (18.8%), and CC1-IV (9.4%). In ST8-IV, MRSA/J and ST8-IV with *spa* type t5071 were identified, with MRSA/J being predominant. The detected MRSA/J, ST8-IV with t5071, and CC1-IV subtypes were similar in terms of drug resistance, molecular characteristics, and phylogenetic features to those detected in the nationwide surveillance. ST8-I was an MRSA-type circulating in the Kyushu region.

**Conclusions:**

The evolving nature of MRSA types in bloodstream infections, correlating with improved outcomes over time and influenced by changes in nationally and regionally circulating strains, is highlighted.

**Keywords:** Whole Genome Sequencing; Sepsis; Methicillin-resistant *Staphylococcus aurus*; Staphylococcal infections; Mortality

## Introduction

Bloodstream infection (BSI) is a severe condition that can lead to sepsis, a systemic inflammatory response. Therefore, administering proper treatment as early as possible is crucial. However, when drug-resistant bacteria cause BSI, appropriate treatment may be delayed. Methicillin-resistant *Staphylococcus aureus* (MRSA) is the most common causative pathogen of BSI.[1,2] In Japan and the USA, the New York/Japan clone, characterized by the presence of the ST5/SCC*mec* II island and multidrug resistance, is the predominant MRSA strain.[3] However, our previous report revealed a decrease in SCC*mec* type II from 79.2% between 2003 and 2007 to 44.9% between 2008 and 2011; conversely, SCC*mec* types I and IV increased.[4] According to a nationwide surveillance conducted in 2019, ST8 carrying SCC*mec* type IV (ST8-IV) and clonal complex 1 carrying SCC*mec* type IV (CC1-IV) were the predominant molecular types in BSI.[5] Additionally, ST8-IV is subdivided into several groups based on molecular characteristics.[5] However, owing to the limited number of MRSA strains detected at each facility during the surveillance, it remains undetermined whether similar trends are observed in individual facilities. Furthermore, the differences in the backgrounds of patients infected with various MRSA types remain unknown.

Therefore, in this study, we aimed to investigate how the molecular epidemiological characteristics of MRSA detected in BSIs at our hospital have changed since 2012 and whether they align with the trends observed in the 2019 nationwide surveillance. We also investigated the differences in drug-resistance genes, virulence genes, and patient characteristics, including mortality, among the different MRSA types.

## Materials and methods

*Study design*

Previously,[4,6] we used to collect MRSA strains detected in one or more blood cultures because collecting more than two sets of blood cultures was not a common practice at our hospital. However, the collection of two or more sets of blood cultures has become more common since the 2010s. Therefore, in this study, we collected MRSA strains detected in two or more blood cultures between January 2012 and December 2019 at Nagasaki University Hospital using the same inclusion criteria for as that used for the nationwide surveillance.[5] If MRSA strains were isolated from the same patient several times, only the first strain detected was included in the study. We also collected information regarding blood culture collection location (outpatient or inpatient), the day of hospitalization blood culture collection, antimicrobial use during the 30 days before the onset of BSI, initial antimicrobial regimens for BSI, mortality, and the details required to calculate the Charlson comorbidity index[7] and Sequential Organ Failure Assessment (SOFA) score[8] from the medical records at Nagasaki University Hospital. The MRSA strains were stored in Microbank (Iwaki & Co., Ltd., Tokyo, Japan) at −80°C until further analysis.

*Antimicrobial susceptibility testing*

We measured the minimum inhibitory concentrations (MICs) of ampicillin, oxacillin, cefoxitin, cefazolin, imipenem, meropenem, levofloxacin, erythromycin, clindamycin, minocycline, vancomycin, teicoplanin, linezolid, daptomycin, and arbekacin using broth microdilution testing using a dry plate (Eiken, Tokyo, Japan), according to the manufacturer's instructions. Antimicrobial susceptibility was determined according to the Clinical and Laboratory Standards

Institute guidelines (CLSI M100-Ed31) and the European Committee on Antimicrobial Susceptibility Testing Version 11.0.

*Whole-genome sequencing (WGS)*

All procedures were performed according to the respective manufacturer's instructions. After extracting the DNA from MRSA strains using a Quick-DNA Fungal/Bacterial Kit (ZYMO RESEARCH, Irvine, CA, United States), we performed WGS on the MRSA strains isolated between 2012 and 2015 using an Ion PGM HiQ View OT2 Kit (Thermo Fisher Scientific, Waltham, MA, USA). Enriched samples were loaded onto an Ion 318 chip and sequenced using an IonTorrent Personal Genome Analyzer with an Ion PGM HiQ View Sequencing Kit (Thermo Fisher Scientific). DNA libraries were generated for Ion PGM using the Ion Xpress Plus Fragment Library Kit (4471269; Thermo Fisher Scientific). We performed WGS for the MRSA strains isolated between 2016 and 2019 using the MiSeq system (Illumina, San Diego, CA, United States) and MiSeq Reagent kit v3 (600 cycles) (Illumina). We also performed WGS for MRSA strains isolated between 2012 and 2015, which needed to be retested using the MiSeq system. We generated DNA libraries for the Miseq system using Invitrogen (Waltham, MA, United States) Collibri ES DNA Library Prep Kit for Illumina (A38607096, ThermoFisher Scientific).

*Analysis of molecular characteristics*

Sequence data were assembled using the CLC Genomics Workbench Microbial Genomics Module (Qiagen, Venlo, Netherlands). Multilocus sequence type (MLST) was determined using PubMLST (https://pubmlst.org).[9] We determined the SCC*mec* and spa types using

SCCmecFinder (ver1.2)[10] and spaTyper (software version 1.0 and database version 2023-6-19)[11] on the Center for Genomic Epidemiology website (https://www.genomicepidemiology.org), respectively. Resistance and virulence genes were detected using ResFinder (software version 2023-08-22 and database version 2023-04-12) and VirulenceFinder (software version 2.0.3 and database version 2022-12-02)[12,13] on the Center for Genomic Epidemiology website (https://www.genomicepidemiology.org), respectively. Our previous study revealed very similar bacteriological characteristics between ST1-carrying SCC*mec* type IV (ST1-IV) and ST2725-carrying SCC*mec* type IV (ST2725-IV);[5] further, a preliminary investigation as part of the current study showed that ST1-IV, ST2725-IV, and ST5213-IV had the same characteristics. Hence, we combined the data from ST1-IV, ST2725-IV, and ST5213-IV as CC1-IV. Core-genome MLST (cgMLST) was performed using Ridom SeqSphere+ v.9.0.10 (Ridom GmbH, Münster, Germany. A minimum spanning tree (MST) or unweighted pair group method with arithmetic mean (UPGMA) tree was created based on MLST, cgMLST, and *S. aureus* accessories using Ridom SeqSphere+ (ver. 9). Samples with more than 10% missing values among the data used for the distance calculation were excluded from constructing the MST or UPGMA. For the UPGMA using strains that were detected during the previous nationwide surveillance,[5] we excluded the strains detected at Nagasaki University Hospital to avoid duplication. In UPGMA, a cluster of MRSA strains was classified with a distance of 0.1, and subclusters of ST8 with SCC*mec* type I (ST8-I) and ST8 with SCC*mec* type IV (ST8-IV), CC1 with SCC*mec* type IV (CC1-IV), and ST5 with SCC*mec* type II (ST5-II) were classified with a distance of 0.03.

*Data collection from previous studies*

Data collected during 2003–2007 and 2008–2011 have been reported previously.[4,6] In this study, we compared the new data with the data from the previous study database to confirm the changes in SCC*mec* type and patient characteristics. To match the study period of previous studies with that of this study, the SCC*mec* type data obtained in this study were analyzed separately for four years, 2012–2015 and 2016–2019.

*Statistical analysis*

All statistical analyses were performed on GraphPad Prism 10 (version 10.1.0; GraphPad Software, Boston, MA, United States of America). Continuous variables were expressed as mean ± standard deviation. Categorical variables were compared using Fisher's exact test, and q values were calculated using the Benjamini–Hochberg method for multiple comparisons. Continuous variables were compared using Student's t-test for two-group comparisons and Tukey's test for multiple comparisons. The statistical significance level was set at $p < 0.05$ and $q < 0.05$, and the $p$-value was considered not significant (n.s.) if it was greater than 0.2.

*Ethics*

This study was approved by the Ethics Committee of the Nagasaki University Hospital (20072018). MRSA strains collected from blood cultures were anonymized and individually numbered. Patient information collected from the medical records was also anonymized and individually numbered when. The Ethics Committee of Nagasaki University Hospital waived the requirement for informed consent.

*Data availability:*

Raw data were generated at the Nagasaki University Hospital. The derived data supporting the findings of this study are presented in the paper and supplementary tables and figures. The WGS data reported in this study are available in the NCBI Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra) under the accession number PRJNA1065106. WGS data from the previous nationwide surveillance[5] are available in the DDBJ Sequence Read Archive (https://www.ddbj.nig.ac.jp/dra/index-e.html) under the accession number DRA013058.

## Results

*Changes in SCCmec type and patient characteristics from 2003 to 2019*

Twenty-seven and fifty-eight MRSA strains were isolated during 2012–2015 and 2016–2019, respectively. The percentages of SCC*mec* types I, II, and IV during 2012–2015 were 37.0%, 37.0%, and 25.9%, respectively. The percentages of SCC*mec* types I, II, IV, and V during 2016–2019 were 15.5%, 15.5%, 65.5%, and 3.4%, respectively. Fig. 1A and Supplementary Table 1 show the changes in SCC*mec* type from 2003 to 2019. SCC*mec* type II was the most frequently detected type during 2003– 2015. However, its frequency decreased significantly from 79.2% during 2003–2007 to 15.5% during 2016–2019 ($q < 0.001$). In contrast, the percentage of SCC*mec* type IV increased dramatically from 18.2% during 2003–2007 to 65.5% during 2016–2019 ($q < 0.001$). SCC*mec* type I showed changes that were different from those of SCC*mec* types II and IV. The percentage of SCC*mec* type I cases increased significantly from 2.6% during 2003–2007 to 37.0% during 2012–2015 ($q < 0.001$). SCC*mec* type I was one of the most frequently detected SCC*mec* types during 2012–2015; however, its prevalence decreased by more than 50% (15.5 %) during 2016–2019.

Table 1 and Supplementary Table 1 show the characteristics of patients in each study period. There were no significant differences in the patients' backgrounds, such as age, sex, or underlying diseases, except for the classification of infection; the percentage of healthcare-associated infections was significantly higher during 2012–2015 than during 2008–2011 (3.6% vs. 22.2%, $q = 0.020$). Further, the sources of MRSA infection changed from 2003 to 2019. The percentage of intravascular device-related BSI increased significantly from 18.1% during 2003–2007 to 46.6% during 2016–2019 ($q = 0.002$). In contrast, the percentage of respiratory tract infection-related BSI significantly decreased from 16.9% during 2003–2007 to 20.5% during 2008–2011 and 1.7% during 2016–2019 ($q = 0.013$ and 0.004, respectively). The severity of BSI also changed between 2003 and 2019. SOFA score significantly decreased from 5.8 ± 0.5 during 2003–2007 to 3.1 ± 0.5 during 2016–2019 ($p = 0.004$), and accordingly, the in-hospital mortality improved from 39.8% during 2003–2007 to 15.5% during 2016–2019 ($q = 0.015$).

*MRSA types based on ST and SCCmec type during 2012–2019*

The changes in ST during the study period are shown in Fig. 1B. ST8 was the predominant ST in both 2012–2015 and 2016–2019, at 63.0% and 62.1%, respectively. However, the percentages of ST5 and CC1 differed; ST5 was lower during 2016–2019 (17.2%) than during 2012–2015 (33.3%), whereas CC1 was detected only during 2016–2019 (13.8%).

The major combinations of ST and SCC*mec* types are shown in Fig. 1C and Supplementary Table 2. Although there was no change in the percentage of ST8 between 2012–2015 and 2016–2019, the combination of SCC*mec* type with ST8 differed between the two periods. The percentage of ST8 with SCC*mec* type IV (ST8-IV) was significantly higher during 2016–2019 (44.8%) than during 2012–2015 (22.2%). In contrast, the percentage of ST8 with SCC*mec* type I

(ST8-I) was significantly lower during 2016–2019 (15.5%) than during 2012–2015 (37.0%; $p$ = 0.048). The predominant combination during this study, i.e., during 2012–2019, was ST8-IV (37.6%), followed by ST8-I (22.4%), ST5 with SCC*mec* type II (ST5-II) (18.8%), and CC1-IV (9.4%) (Supplementary Fig. 1).

*Patient characteristics and drug-resistance rate in the major MRSA types*

Table 2 and Supplementary Table 3 show the patient characteristics for each major combination. No significant differences were observed in with respect to the patient characteristics among the major MRSA types. The SOFA score and in-hospital mortality were lower for CC1-IV, with 2.3 ± 0.6 and 12.5%, respectively, than those of other major MRSA types; however, there was no statistical difference.

The drug-resistance rates of the major MRSA types to different antimicrobial agents in are shown in Table 2 and Supplementary Table 3. The levofloxacin resistance rate was significantly lower in ST8-IV than in all the other major MRSA types ($q$ = 0.002 vs. ST8-I and ST5-II and $q$ = 0.032 vs. CC1-IV). The erythromycin resistance rate was also significantly lower in ST8-IV than in ST8-I. In contrast, the clindamycin resistance rate of ST5-II was significantly higher than that of all other major MRSA types ($q$ < 0.001 for all comparisons). CLSI and EUCAST guidelines differ in their protocols for the determination of minocycline resistance rates. All strains were sensitive to minocycline per the CLSI guidelines; however, when tested according to the EUCAST guidelines, a difference in minocycline resistance rates was observed among the major MRSA types . The minocycline resistance rate was significantly higher in ST8-I and ST5-II types than in ST8-IV and CC1-IV types. There were also differences in the MICs of beta-lactams, for which breakpoints for MRSA were not set by the CLSI or EUCAST. The MICs of

cefazolin, imipenem, and meropenem were lower for ST8-IV and CC1-IV than for ST8-I and ST5-II (Supplementary Fig. 2C-F). The MICs of imipenem against most strains belonging to the ST8-IV and CC1-IV type were less than 0.5, in contrast to those of the ST8-I and ST5-II types, which were higher than 16 (Supplementary Fig. 2E).

*Molecular characteristics of the strains in the major MRSA types*

Drug-resistance and virulence genes differed among the major MRSA types. Although ST8-IV and ST8-I belonged to the same sequence type, the positivity rates for drug-resistance genes, such as *aadD, ant(9)-Ia, erm(A), tet(M),* and *bleO,* in ST8-I were significantly higher than those in ST8-IV (Fig. 2A). ST8-I showed a similar trend with respect to its drug-resistance genes as that shown by ST5-II, except for *aac(6′)-aph(2″*). However, the positivity rates for the virulence genes differed between ST8-I and ST5-II. The positivity rates for *sec*, *seg*, *sei*, *sel*, *sem*, *seo*, *sep*, *seu*, and *tst* were significantly higher in ST5-II than in ST8-I. In contrast, the positivity rate for *splE* was significantly lower in ST5-II than that in ST8-I (Fig. 2B). CC1-IV has characteristic virulence gene features. It harbors virulence genes such as *sea*, *seh*, *sek*, and *seq,* which are not present in other major MRSA types.

In ST8-IV, the positivity rates for drug-resistance and virulence genes, such as *aac(6′)-aph(2″)*, *aadD*, *ant(9)-Ia*, *erm(A)*, *bleO*, *sec*, *sel*, *sep*, *tst*, and *splE*, were around 50% (Fig. 2). Phylogenetic analysis based on core genome MLST revealed that ST8-IV was divided into several clusters (Supplementary Fig. 3). Based on the results of the virulence genes *sec* and *tst* and the *spa* type,[5] 14 and 4 strains were classified as CA-MRSA/J and ST8-IV with t5071, respectively. There were significant differences between CA-MRSA/J and ST8-IV strains with respect to t5071 expression (Supplementary Table 4). The positive rates for *aac(6′)-aph(2″),*

*aadD, bleO, sec, sel,* and *tst* were significantly higher in CA-MRSA/J than in ST8-IV with t5071 ($p < 0.05$), and those for *ant(9)-Ia, erm(A), splE,* and *sep* were significantly lower in CA-MRSA/J than in ST8-IV with t5071 ($p < 0.05$). Based on antimicrobial susceptibility testing, CA-MRSA/J was more sensitive to levofloxacin, erythromycin, clindamycin, and minocycline than was ST8-IV with t5071 ($p < 0.05$) (Supplementary Table 4).

*Relationship between the strains detected in Nagasaki and those circulating in Japan*

Phylogenetic tree analysis based on MLST, cgMLST, and *S. aureus* accessory sequences was performed to investigate the relationship between the strains detected in this study and those from the previous nationwide surveillance.[5] Based on the phylogenetic tree analysis, the strains were divided into three major clusters, ST8-IV and ST8-I, CC1-IV, and ST5-II (Supplementary Fig. 4). In the ST8-IV and ST8-I clusters (Fig. 3A), most ST8-I strains detected in Nagasaki and the nationwide surveillance were classified into subcluster 3, whereas ST8-IV was divided into ten subgroups. However, in the ST8-IV group, all CA-MRSA/J strains detected in Nagasaki and nationwide were classified into subcluster 1. All ST8-IV with t5071 strains detected in Nagasaki and nationwide were classified into subcluster 5. The ST5-II strains showed the same trend as that of the ST8-IV strains. The ST5-II strains detected in Nagasaki were divided into five subclusters (Fig. 3B). In contrast to ST8-IV and ST5-II, most CC1-IV strains detected in Nagasaki and nationwide surveillance were classified into the same sub-cluster 12.

## Discussion

This study revealed that SCC*mec* type II has progressively declined since the 2000s, whereas SCC*mec* type IV has quickly become the predominant SCC*mec* type since the mid-2010s in

patients with BSIs. SCC*mec* type II, represented by the NY/J clone (ST5-II), is the predominant MRSA causing BSIs in both the United States and Japan.[3] However, in the United States, SCC*mec* type IV has increased in prevalence and replaced SCC*mec* type II in BSIs since the late 2000s.[14] Based on the results from the two nationwide surveillance conducted in Japan, the prevalence of SCC*mec* type IV increased from 19.9% in 2011 to 77.4% in 2019, whereas that of SCC*mec* type II decreased to 7.8% in 2019 from 75.6% in 2011.[5,15] In addition, according to a previous Japanese study conducted in the Kanto region, the prevalence of SCC*mec* type IV was higher than that of SCC*mec* type II in 2016,[16] which is similar to the results of this study. In the present study, the percentage of SCC*mec* type IV cases remained between 20% and 30% until 2012–2015 but increased rapidly thereafter. These results indicate that the shift from SCC*mec* type II to IV occurred almost simultaneously throughout Japan in the mid-2010s.

Although SCC*mec* type IV is the predominant SCC*mec* type in both the United States and Japan, its molecular characteristics differ. The USA300-like clone (ST8-IV with t008) was the most common MRSA type in the United States,[14] the percentage of the clone was only 3.3% in Japan in 2019,[5] which is similar to the results of this study (5.9 %). In Japan, two significant types of ST8-IV circulate: CA-MRSA/J and ST8-IV with t5071.[5] In this study, although CA-MRSA/J was the predominant strain of ST8-IV, ST8-IV with t5071 was not frequently detected. This was unsurprising because ST8-IV with t5071 were primarily detected in the Kinki region.[5] Another feature that differed between the United States and Japan was the higher prevalence of CC1-IV was than that of ST8-IV in Japan.[5] However, there were regional differences in the ratios of CC1-IV and ST8-IV: the percentage of CC1-IV was much higher than that of ST8-IV in eastern Japan, whereas the percentage of ST8-IV was much higher than that of CC1-IV in western Japan, including the Kyushu region, where Nagasaki belongs.[5] This study demonstrated

results similar to the regional patterns identified in the nationwide surveillance, with a much higher percentage of ST8-IV than CC1-IV. However, the percentage of CC1-IV cases may increase in Nagasaki. A previous study conducted in Hokkaido reported a rapidly increasing percentage of CC1-IV in BSIs in 2019.[17] In addition, in a single-center study conducted in the Kyushu region during 2018–2019, the percentage of CC1-IV was 14.2% in blood cultures, whereas, it was 59.0% and 77.3% in sputum and skin and soft tissues, respectively.[18] Considering that CC1-IV was detected only after 2016 in this study, it is possible that we only observed the early stages of CC1-IV circulation in our region.

The CA-MRSA/J, ST8-IV with t5071, and CC1-IV types detected in Nagasaki and during the nationwide surveillance[5] were classified into the same subcluster during phylogenetic analysis. The drug susceptibility characteristic trends in our study were similar to those in the national surveillance[5] for most cases. In both studies, the following differences among the major types were observed. CA-MRSA/J was sensitive to levofloxacin; CA-MRSA/J and CC1-IV were sensitive to clindamycin, whilst ST8-IV with t5071 was resistant; for minocycline, all types were sensitive according to CLIS criteria, whereas ST8-IV with t5071 had a very high rate of resistance according to the EUCAST criteria. The positivity rates for drug-resistance genes showed the same trends in both studies. Almost all CC1-IV and ST8-IV with t5071 harbored *ant(9)-Ia* and *erm* (A), whereas the positivity rates for these genes were low in CA-MRSA/J. In contrast, the positivity rates for *aac(6')-aph(2'')* and *aadD* were much higher in CA-MRSA/J than in CC1-IV or ST8-IV with t5071. The positivity rates for virulence genes showed the same trend in both studies. The virulence genes *sea, seh, sek,* and *seq* were harbored by the CC1-IV type but not the other two types. Similarly, CA-MRSA/J, but not the other two types, harbored *sec, sel,* and *tst*. In contrast, CA-MRSA/J did not harbor *splE,* whereas the other two types

frequently harbored *splE*. These results suggest that CA-MRSA/J, ST8-IV with t5071, and CC1-IV have spread across the nation rapidly with the same molecular background and characteristics.

However, trends differing from that of the nationwide surveillance were also observed in the present study. In our hospital, the prevalence of ST8-I increased during 2003–2015 and became the predominant MRSA type during 2012–2015, which means that ST8-I replaced ST5-II by 2015. Unlike the SCC*mec* type IV strains, ST8-I showed a similar trend to that of ST5-II with respect to drug resistance. The difference from ST5-II was that ST8-I was more sensitive to clindamycin and exhibited higher positivity rates for *aac(6')-aph(2'')* and *aadD.* In contrast, their virulence genes were completely different, with ST8-I having markedly fewer virulence factors than did ST5-II. With respect to virulence genes, ST8-I showed a trend similar to that of ST8-IV with t5071; however, *sed, sej,* and *ser* were detected only in ST8-I. In the nationwide surveillance study, there were four ST8-I strains, three of which were detected in the Kyushu region.[5] During phylogenetic analysis, most ST8-I strains detected in Nagasaki and across the nation were classified into the same subcluster. In a previous single-center study in the Kyushu region, ST8-I was the second most frequently detected type during 2018–2019.[18] Additionally, a certain percentage of SCC*mec* type I strains were detected in several studies in the Kyushu region.[19–21] These results indicated that ST8-I spread independently in the Kyushu region.

In the current study, we investigated the changes in patient characteristics. Although patient backgrounds such as age, sex, and underlying disease did not change from 2003 to 2019, in-hospital mortality reduced significantly from 39.8% during 2003–2007 to 15.5% during 2016–2019. As reported in a previous study,[4] the proper use of vancomycin might have contributed to this improvement owing to the increase in the percentage of vancomycin used for initial anti-

MRSA treatment between 2003 and 2019. However, this study also showed a reduction in severity, which was not observed in previous studies. The average SOFA score significantly decreased from 5.8 during 2003–2007 to 3.1 during 2016–2019. In addition, the source of MRSA infection has changed. The percentage of patients with intravascular device-related BSI was much higher during 2016–2019 than during 2003–2007, whereas that of patients with respiratory tract infections was much lower during 2016–2019 than during 2003–2007. We also compared the patient characteristics among the major MRSA types. The average SOFA score in patients carrying the ST5-II type was 4.4, which was higher than those in patients with ST8-IV, ST8-I, or CC1-IV (3.4, 3.5, and 2.3, respectively) types. The in-hospital mortality showed the same trend for each MRSA type. In contrast, the percentage of patients with respiratory tract infection was higher in ST5-II (18.8%) than in ST8-IV, ST8-I, and CC1-IV (0%, 5.3%, and 0%, respectively). However, the initial anti-MRSA treatment did not differ considerably based on the MRSA types. Because the prevalence of ST5-II decreased and those of ST8-IV and CC1-IV increased from 2003 to 2019 and there was no change in patient background, the changes in MRSA types may have reduced the severity and in-hospital mortality.

This study has several limitations. First, because this was a single-center study, it is unclear whether the differences in patient characteristics for each MRSA type can be generalized. Second, to reduce the likelihood of contamination, we included only cases that were positive for at least two sets of blood cultures. This inclusion criterion is the same as that used in the nationwide surveillance[5] but different from that used in our previous studies.[4,6] Cases with at least one positive set of blood cultures were included in the previous studies[4,6] because it was not a common practice then in our hospital to collect more than two sets of blood cultures. This difference in inclusion criteria may have influenced the patients' backgrounds. However,

because mortality and SOFA scores were low during the present study period, the number of contamination cases may not be very high in the previous studies. Third, there were several strains for which the *spa* type was not determined or was excluded from the phylogenetic analysis: 22 of 85 strains (25.9%) and 10 of 75 strains (13.3%), respectively. This is a limitation that also holds true for the nationwide surveillance.[5]

## Conclusions

This study demonstrated that the major MRSA types in BSIs changed over time and were associated with reduced disease severity and in-hospital mortality. In addition, changes in the major MRSA types were directly influenced by changes in the circulating strains nationally and regionally. Such epidemiological studies are necessary because MRSA types are expected to continue changing.

## Conflicts of interest

The authors have no conflicts to declare.

**Funding:** This work was supported by the Japanese Association for Infectious Diseases (The 1st Grant for Clinical Research Promotion, 2018) and the Japanese Antibiotics Research Association (The 23rd Encouragement Award, 2021). The funders had no role in the data analysis or the decision to publish.

**Acknowledgments:** We thank Mr. Shuji Miyazaki (Department of Laboratory Medicine, Nagasaki University of Hospital) for supporting the analysis of MRSA strains. We would like to thank Editage (www.editage.jp) for English language editing.

**Author contributions**

N. K. and K. Y. designed the experiments. N. K., M. I., G. Y., and D. S. acquired the data. N.K., K.O., F. M. K., K.K., H.H., K.I., H.M., and K.Y. analyzed the data. N.K. wrote the manuscript. All the authors have revised and approved the manuscript for publication.

**References**

1 Tsuzuki Shinya, Matsunaga Nobuaki, Yahara Koji, Shibayama Keigo, Sugai Motoyuki, Ohmagari Norio. Disease burden of bloodstream infections caused by antimicrobial-resistant bacteria: A population-level study, Japan, 2015–2018. *International Journal of Infectious Diseases* 2021;**108**:119–24. Doi: 10.1016/J.IJID.2021.05.018.

2 Kern W. V., Rieg S. Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens. *Clin Microbiol Infect* 2020;**26**(2):151–7. Doi: 10.1016/J.CMI.2019.10.031.

3 Yamamoto Tatsuo, Nishiyama Akihito, Takano Tomomi, Yabe Shizuka, Higuchi Wataru, Razvina Olga, et al. Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistance. *Journal of Infection and Chemotherapy* 2010;**16**(4):225–54. Doi: 10.1007/S10156-010-0045-9.

4 Kaku Norihito, Yanagihara Katsunori, Morinaga Yoshitomo, Yamada Koichi, Harada Yosuke, Migiyama Yohei, et al. Influence of antimicrobial regimen on decreased in-

hospital mortality of patients with MRSA bacteremia. *Journal of Infection and Chemotherapy* 2014;**20**(6):350–5. Doi: 10.1016/J.JIAC.2013.12.009.

5 Kaku Norihito, Sasaki Daisuke, Ota Kenji, Miyazaki Taiga, Yanagihara Katsunori. Changing molecular epidemiology and characteristics of MRSA isolated from bloodstream infections: nationwide surveillance in Japan in 2019. *J Antimicrob Chemother* 2022;**77**(8):2130–41. Doi: 10.1093/JAC/DKAC154.

6 Motoshima Maiko, Yanagihara Katsunori, Morinaga Yoshitomo, Matsuda Junichi, Sugahara Kazuyuki, Yamada Yasuaki, et al. Genetic diagnosis of community-acquired MRSA: a multiplex real-time PCR method for Staphylococcal cassette chromosome mec typing and detecting toxin genes. *Tohoku J Exp Med* 2010;**220**(2):165–70. Doi: 10.1620/TJEM.220.165.

7 Charlson Mary, Szatrowski Ted P., Peterson Janey, Gold Jeffrey. Validation of a combined comorbidity index. *J Clin Epidemiol* 1994;**47**(11):1245–51. Doi: 10.1016/0895-4356(94)90129-5.

8 Singer Mervyn, Deutschman Clifford S., Seymour Christopher Warren, Shankar-Hari Manu, Annane Djillali, Bauer Michael, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;**315**(8):801–10. Doi: 10.1001/JAMA.2016.0287.

9 Jolley Keith A., Bray James E., Maiden Martin C.J. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications [version 1; referees: 2 approved]. *Wellcome Open Res* 2018;**3**. Doi: 10.12688/WELLCOMEOPENRES.14826.1/DOI.

10 Kaya Hülya, Hasman Henrik, Larsen Jesper, Stegger Marc, Johannesen Thor Bech, Allesøe Rosa Lundbye, et al. SCC mec Finder, a Web-Based Tool for Typing of Staphylococcal Cassette Chromosome mec in Staphylococcus aureus Using Whole-Genome Sequence Data. *MSphere* 2018;**3**(1):e00612-17. Doi: 10.1128/MSPHERE.00612-17.

11 Bartels Mette Damkjær, Petersen Andreas, Worning Peder, Nielsen Jesper Boye, Larner-Svensson Hanna, Johansen Helle Krogh, et al. Comparing whole-genome sequencing with Sanger sequencing for spa typing of methicillin-resistant Staphylococcus aureus. *J Clin Microbiol* 2014;**52**(12):4305–8. Doi: 10.1128/JCM.01979-14.

12 Tetzschner Anna Maria Malberg, Johnson James R., Johnston Brian D., Lund Ole, Scheutz Flemming. In Silico Genotyping of Escherichia coli Isolates for Extraintestinal Virulence Genes by Use of Whole-Genome Sequencing Data. *J Clin Microbiol* 2020;**58**(10). Doi: 10.1128/JCM.01269-20.

13 Joensen Katrine Grimstrup, Scheutz Flemming, Lund Ole, Hasman Henrik, Kaas Rolf S., Nielsen Eva M., et al. Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic Escherichia coli. *J Clin Microbiol* 2014;**52**(5):1501–10. Doi: 10.1128/JCM.03617-13.

14 Tickler Isabella A., Goering Richard V., Mediavilla Jose R., Kreiswirth Barry N., Tenover Fred C. Continued expansion of USA300-like methicillin-resistant Staphylococcus aureus (MRSA) among hospitalized patients in the United States. *Diagn Microbiol Infect Dis* 2017;**88**(4):342–7. Doi: 10.1016/J.DIAGMICROBIO.2017.04.016.

15 Miura Yuri, Yamaguchi Tetsuo, Nakamura Itaru, Koyama Shinobu, Tamai Kiyoko, Okanda Takashi, et al. Epidemiological Trends Observed from Molecular

Characterization of Methicillin-Resistant Staphylococcus aureus Isolates from Blood Cultures at a Japanese University Hospital, 2012–2015. *Microbial Drug Resistance* 2018;**24**(1):70–5. Doi: 10.1089/mdr.2017.0008.

16 Hamada Masakaze, Yamaguchi Tetsuo, Sato Ayami, Ono Daisuke, Aoki Kotaro, Kajiwara Chiaki, et al. Increased Incidence and Plasma-Biofilm Formation Ability of SCC mec Type IV Methicillin-Resistant Staphylococcus aureus (MRSA) Isolated From Patients With Bacteremia. *Front Cell Infect Microbiol* 2021;**11**. Doi: 10.3389/FCIMB.2021.602833.

17 Aung Meiji Soe, Urushibara Noriko, Kawaguchiya Mitsuyo, Ohashi Nobuhide, Hirose Mina, Kimura Yuuki, et al. Molecular Epidemiological Characterization of Methicillin-Resistant Staphylococcus aureus from Bloodstream Infections in Northern Japan: Increasing Trend of CC1 and Identification of ST8-SCCmec IVa USA300-Like Isolate Lacking Arginine Catabolic Mobile Element n.d. Doi: 10.1089/mdr.2023.0203.

18 Mitsumoto-Kaseida Fujiko, Morinaga Yoshitomo, Sasaki Daisuke, Ota Kenji, Kaku Norihito, Sakamoto Kei, et al. The clinical characteristics and molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) among very elderly people in Japan. *Geriatr Gerontol Int* 2023;**23**(10):744–9. Doi: 10.1111/GGI.14664.

19 Kimura Yumiko, Morinaga Yoshitomo, Akamatsu Norihiko, Matsuda Junichi, Yamaryo Takeshi, Kawakami Kenji, et al. Antimicrobial susceptibility and molecular characteristics of methicillin-resistant Staphylococcus aureus in a Japanese secondary care facility. *Journal of Infection and Chemotherapy* 2016;**22**(1):14–8. Doi: 10.1016/J.JIAC.2015.08.011.

20 Nakano Yuki, Murata Masayuki, Matsumoto Yuji, Toyoda Kazuhiro, Ota Azusa, Yamasaki Sho, et al. Clinical characteristics and factors related to infection with SCC mec type II and IV Methicillin-resistant Staphylococcus aureus in a Japanese secondary care facility: a single-center retrospective study. *J Glob Antimicrob Resist* 2022;**31**:355–62. Doi: 10.1016/j.jgar.2022.11.003.

21 Mitsumoto-Kaseida Fujiko, Murata Masayuki, Toyoda Kazuhiro, Morokuma Yuiko, Kiyosuke Makiko, Kang Dongchon, et al. Clinical and pathogenic features of SCCmec type II and IV methicillin-resistant Staphylococcus aureus in Japan. *Journal of Infection and Chemotherapy* 2017;**23**(2):90–5. Doi: 10.1016/J.JIAC.2016.11.001.

**Tables**

**Table 1. Changes in patient characteristics from 2003 to 2019**

| | 2003–2007<br>n = 83 | 2008–2011<br>n = 83 | 2012–2015<br>n = 27 | 2016–2019<br>n = 58 |
|---|---|---|---|---|
| Age, average | 63.7 ± 1.9 | 67.3 ± 1.6 | 69.1 ± 3.2 | 63.4 ± 3.2 |
| Sex, female | 47.0% | 30.1% | 25.9% | 36.2% |
| Charlson comorbidity index | 3.0 ± 0.2 | 3.1 ± 0.2 | 4.0 ± 0.5 | 3.2 ± 0.3 |
| Number of days of hospitalization after MRSA detection | No data | 41.9 ± 6.3 | 38.5 ± 6.3 | 36.1 ± 7.9 |
| Antimicrobial use during the 30 days before MRSA detection | No data | 75.9% | 59.3% | 60.3% |
| Classification of infection | | | | |
| Community-acquired | No data | 3.6% | - | 8.6% |
| Healthcare-associated | No data | 3.6% | 22.2% | 13.8% |
| Hospital-acquired | No data | 86.7% | 77.8% | 77.6% |
| Source of MRSA infection | | | | |
| Intravascular device | 18.1% | 30.1% | 29.6% | 46.6% |
| Respiratory tract | 16.9% | 20.5% | 11.1% | 1.7% |
| Skin/soft tissue or surgical site | 10.8% | 15.7% | 25.9% | 13.8% |
| Abdomen | 7.2% | 4.8% | - | 8.6% |
| Bone and joint | 13.3% | 2.4% | 11.1% | 8.6% |
| Others | 7.2% | 6.0% | 11.1% | 3.4% |
| Unknown | 26.5% | 20.5% | 11.1% | 17.2% |
| SOFA score | 5.8 ± 0.5 | 5.8 ± 0.5 | 4.2 ± 0.9 | 3.1 ± 0.4 |
| Initial antimicrobial chemotherapy against MRSA | | | | |
| Vancomycin | 28.9% | 45.8% | 55.6% | 69.0% |
| Teicoplanin | 39.8% | 13.3% | 11.1% | 5.2% |
| Linezolid | 10.8% | 21.7% | 25.9% | 1.7% |
| Daptomycin | - | - | 11.1% | 20.7% |
| Arbekacin | 3.6% | 1.2% | - | - |
| No anti-MRSA agents | 16.9% | 19.3% | - | 5.2% |
| Change of initial treatment | 34.9% | 30.1% | 25.9% | 37.9% |
| In-hospital mortality | 39.8% | 25.3% | 37.0% | 15.5% |
| 30-day mortality | No data | 18.1% | 18.5% | 10.3% |

**Table 2. Patient characteristics and drug-resistance rates according to the major MRSA types**

| | ST8-IV<br>n = 32 | ST8-I<br>n = 19 | ST5-II<br>n = 16 | CC1-IV<br>n = 8 |
|---|---|---|---|---|
| Age, average | 67.4 ± 3.9 | 65.6 ± 5.4 | 63.5 ± 5.3 | 68.1 ± 4.3 |
| Sex, female | 34.4% | 21.1% | 43.8% | 62.5% |
| Charlson comorbidity index | 3.1 ± 0.5 | 4.8 ± 0.7 | 3.1 ± 0.5 | 3.0 ± 0.8 |
| Number of hospitalization days after MRSA detection | 40.2 ± 8.1 | 32.6 ± 7.0 | 57.8 ± 26.9 | 48.1 ± 12.1 |
| Antimicrobial use during the 30 days before MRSA detection | 62.5% | 47.4% | 68.8% | 62.5% |
| Classification of infection | | | | |
| Community-acquired | 6.3% | 5.3% | 6.3% | - |
| Healthcare-associated | 12.5% | 21.1% | 12.5% | - |
| Hospital-acquired | 81.3% | 73.7% | 81.3% | 100% |
| Source of MRSA infection | | | | |
| Intravascular device | 40.6% | 47.4% | 43.8% | 25.0% |
| Respiratory tract | - | 5.3% | 18.8% | - |
| Skin/soft tissue or surgical site | 21.9% | 10.5% | 12.6% | 12.5% |
| Abdomen | 6.3% | 5.3% | 6.3% | 12.5% |
| Bone and joint | 6.3% | 15.8% | 6.3% | - |
| Others | 3.1% | 10.5% | 6.3% | 12.5% |
| Unknown | 21.9% | 5.35 | 6.3% | 37.5% |
| SOFA score | 3.4 ± 0.7 | 3.5 ± 0.9 | 4.4 ± 1.1 | 2.3 ± 0.6 |
| Initial antimicrobial chemotherapy against MRSA | | | | |
| Vancomycin | 68.8% | 62.3% | 62.5% | 62.5% |
| Teicoplanin | 6.3% | 5.3% | 6.3% | 12.5% |
| Linezolid | 9.4% | 15.8% | 12.5% | - |
| Daptomycin | 18.8% | 15.8% | 18.8% | 12.5% |
| No anti-MRSA agents | - | 5.3% | - | 12.5% |
| Change of initial treatment | 43.8% | 31.6% | 37.5% | 25.0% |
| In-hospital mortality | 21.9% | 26.3% | 31.3% | 12.5% |
| 30-day mortality | 12.5% | 10.5% | 25.0% | 12.5% |
| Drug-resistance rates according to CLSI/EUCAST guidelines | | | | |
| Oxacillin | 96.9% / 96.9% | 100% / 100% | 100% / 100% | 87.5% / 87.5% |
| Cefoxitin | 100% / 100% | 100% / 100% | 100% / 100% | 100% / 100% |
| Levofloxacin | 53.1% / 53.1% | 100% / 100% | 100% / 100% | 100% / 100% |
| Erythromycin | 68.8% / 71.9% | 100% / 100% | 100% / 100% | 87.5% / 87.5% |
| Clindamycin | 28.1% / 31.3% | 36.8% / 36.8% | 100% / 100% | 25.0% / 25.0% |
| Minocycline | 0% / 21.9% | 0% / 89.5% | 0% / 68.8% | 0% / 12.5% |
| Vancomycin | 0% / 0% | 0% / 0% | 0% / 0% | 0% / 0% |
| Teicoplanin | 0% / 0% | 0% / 0% | 0% / 0% | 0% / 0% |
| Linezolid | 0% / 0% | 5.3% / 5.3% | 6.3% / 6.3% | 0% / 0% |

**Figure legends**

**Fig. 1. Changes in SCC*mec* type, sequence type, and their combinations**

Changes in SCC*mec* type from 2003 to 2019 (**A**) and sequence type (ST) from 2012 to 2019 (**B**) were evaluated. The percentage of major MRSA types based on the SCC*mec* type and ST from 2012 to 2019 was also evaluated (**C**). Data regarding SCC*mec* type during 2003–2007 and 2008–2011 have been reported previously. (**B**) We decided on ST based on whole-genome sequencing using the CLC Genomics Workbench and the CLC Microbial Genomics Module (Qiagen, Venlo, Netherlands). The inclusion criteria for MRSA strains in this study (2012–2015 and 2016–2019) differed from those used in previous studies (2003–2007 and 2008–2011). In previous studies, MRSA strains collected from one or more blood cultures were analyzed, whereas in this study, MRSA strains collected from two or more blood cultures were analyzed.

**Fig. 2. The positivity rates for drug-resistance and virulence genes in the major MRSA types**

Drug-resistance (**A**) and virulence (**B**) genes were detected after whole-genome sequencing using ResFinder and virulence finder, respectively.

**Fig. 3. Phylogenetic analysis of MRSA strains detected in Nagasaki and those circulating in Japan**

Phylogenetic tree analysis was performed based on MLST, core genome MLST (cgMLST), and *S. aureus* accessory sequences to investigate the relationship between the strains detected in this study and those from the previous nationwide surveillance. Based on the phylogenetic tree analysis of all strains (Supplementary Fig. 4), the strains were divided into three major clusters: ST8-IV and ST8-I (**A**), CC1-IV (**B**), and ST5-II (**C**). cgMLST was performed using the Ridom SeqSphere+ v.9.0.10 (Ridom GmbH, Münster, Germany). A UPGMA tree was created based on

MLST, cgMLST, and *S. aureus* accessory genes. Samples with more than 10% missing values among the data used for distance calculation were excluded. During UPGMA of the strains detected during the previous nationwide surveillance, the strains detected at Nagasaki University Hospital were excluded to avoid duplication.




**Fig. 1. Changes in SCC*mec* type, sequence type, and their combinations**

Changes in SCC*mec* type from 2003 to 2019 (**A**) and sequence type (ST) from 2012 to 2019 (**B**) were evaluated. The percentage of major MRSA types based on the SCC*mec* type and ST from 2012 to 2019 was also evaluated (**C**). Data regarding SCC*mec* type during 2003–2007 and 2008–2011 have been reported previously. (**B**) We decided on ST based on whole-genome sequencing using the CLC Genomics Workbench and the CLC Microbial Genomics Module (Qiagen, Venlo, Netherlands). The inclusion criteria for MRSA strains in this study (2012–2015 and 2016–2019) differed from those used in previous studies (2003–2007 and 2008–2011). In previous studies, MRSA strains collected from one or more blood cultures were analyzed, whereas in this study, MRSA strains collected from two or more blood cultures were analyzed.




**Fig. 2. The positivity rates for drug-resistance and virulence genes in the major MRSA types**

Drug-resistance (**A**) and virulence (**B**) genes were detected after whole-genome sequencing using ResFinder and virulence finder, respectively.




**Fig. 3. Phylogenetic analysis of MRSA strains detected in Nagasaki and those circulating in Japan**

Phylogenetic tree analysis was performed based on MLST, core genome MLST (cgMLST), and *S. aureus* accessory sequences to investigate the relationship between the strains detected in this study and those from the previous nationwide surveillance. Based on the phylogenetic tree analysis of all strains (Supplementary Fig. 4), the strains were divided into three major clusters: ST8-IV and ST8-I (**A**), CC1-IV (**B**), and ST5-II (**C**). cgMLST was performed using the Ridom SeqSphere+ v.9.0.10 (Ridom GmbH, Münster, Germany). A UPGMA tree was created based on MLST, cgMLST, and *S. aureus* accessory genes. Samples with more than 10% missing values among the data used for distance calculation were excluded. During UPGMA of the strains detected during the previous nationwide surveillance, the strains detected at Nagasaki University Hospital were excluded to avoid duplication.